city New Delhi India covid-19 recommendations information patient city New Delhi India

Covid-19 Pharma major Mylan gets nod to make remdesivir for 'restricted emergency use'

Reading now: 289
www.livemint.com

New Delhi: After Hetero and Cipla, another pharmaceutical major Mylan was given permission by India's drug regulator on Thursday to manufacture and market the anti-viral drug remdesivir for "restricted emergency use" on hospitalised COVID-19 patients, official sources said.Written informed consent of each patient is required before the use of the drug while active post-marketing surveillance data and reporting of serious adverse events have to be submitted.On June 21, Hetero and Cipla were given permission to manufacture and market the drug on the same conditions.The Union Health ministry in its 'Clinical Management Protocols for COVID-19' recommended the use of the drug in COVID-19 patients with moderate stages of the illness (those on.

Read more on livemint.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA